



COMPANY ANNOUNCEMENT
17 June 2009

BOARD CHANGES AT NEURODISCOVERY

NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience services provider and drug development company, today announces a further change to its board of directors.

Dr Iain Chessell, a non-executive director, is standing down from the board but will continue as a consultant to the Company. As part of earlier re-structuring over the last week, Dr Tony Evans also stood down from the board, following Mr Harry Karelis joining the board as a new non-executive director. Mr Karelis represents Biotech Capital Ltd, which is NeuroDiscovery's major shareholder. Mr Karelis has led investments in drug discovery, regenerative medicine, medical devices and several other technology platform areas.

Dr Mark Treherne, non-executive chairman of NDL commented "we are very pleased to have Harry Karelis join our board with his wealth of relevant experience, as NDL looks to evaluate a number of opportunities to build shareholder value. The Company would like to thank Tony for his contributions to NDL and wishes him every success in the future and we look forward to continuing to work with Iain in his new role as a consultant."

Please find attached Appendix 3Z for Dr Iain Chessell.

-ENDS-

CONTACTS

Company	
David McAuliffe Executive Director	Chris Moyses Chief Executive Officer
T: +61 (0)408 994 313	T: +44 (0)7802 586 573 (after 4pm AEST for UK time zone)
E: macdavid@iinet.net.au	E: CMoyes@neurosolutionsltd.com

About NeuroDiscovery

NeuroDiscovery Ltd is an ASX listed speciality neuroscience services provider and drug development company which owns 100% of NeuroSolutions Ltd (ASX Code NDL).

About NeuroSolutions

NeuroSolutions Limited is a profitable service company, which has applied its broad spectrum expertise and drug discovery platforms to become a leading provider of specialised electrophysiological assays to the biopharmaceutical industry. Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells or tissues. NeuroSolutions' current clients include many established pharmaceutical and biotechnology companies.

In parallel to running its service business, the Company is also exploiting its in-house technologies and expertise for its own internal R&D and has a mature pipeline of programmes underway for the treatment of pain.

During 2008, the Company reported success in a Phase II trial for NSL-101. The Company also successfully completed two Phase I trials for the development compound NSL-043, in partnership with Sosei Co. Ltd. Both of these trials reported a successful outcome.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	NeuroDiscovery Ltd
ABN	89 113 824 141

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Dr Iain Chessell
Date of last notice	1 October 2008
Date that director ceased to be director	15 June 2009

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
435,000 Ordinary Shares.

+ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest	

Part 3 – Director's interests in contracts

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.